Invasive Mucinous Adenocarcinomas with Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.

[1]  L. Borsu,et al.  Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes , 2021, Clinical Cancer Research.

[2]  J. Heymann,et al.  Synchronous Pulmonary Adenocarcinomas. , 2020, American journal of clinical pathology.

[3]  Sarah H. Johnson,et al.  Using genomics to differentiate multiple primaries from metastatic lung cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  David R. Jones,et al.  Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach , 2019, Clinical Cancer Research.

[5]  W. Nie,et al.  Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings , 2019, Cancer Imaging.

[6]  L. Fournel,et al.  Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  M. Ladanyi,et al.  High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden , 2019, Clinical Cancer Research.

[8]  A. Otsuka,et al.  Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. , 2018, JCO precision oncology.

[9]  P. Roepman,et al.  Added Value of 50-Gene Panel Sequencing to Distinguish Multiple Primary Lung Cancers from Pulmonary Metastases: A Systematic Investigation. , 2018, The Journal of molecular diagnostics : JMD.

[10]  Shigemi Matsumoto,et al.  Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. , 2018, The oncologist.

[11]  M. Ladanyi,et al.  Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. , 2018, Cancer discovery.

[12]  A. Marchevsky,et al.  Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases. , 2017, The Journal of molecular diagnostics : JMD.

[13]  H. Shim,et al.  Biology of invasive mucinous adenocarcinoma of the lung. , 2017, Translational lung cancer research.

[14]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[15]  Vamsidhar Velcheti,et al.  HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  K. Shimizu,et al.  Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings , 2016, OncoTargets and therapy.

[17]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[18]  H. Asamura,et al.  Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Stuart J. Andrews,et al.  A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma , 2016, Genome Medicine.

[20]  J. Choi,et al.  Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  K. Nafa,et al.  Locked Nucleic Acid Probes (LNA) for Enhanced Detection of Low-Level, Clinically Significant Mutations. , 2016, Methods in molecular biology.

[22]  Maristela L Onozato,et al.  Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[24]  Jingyun Shi,et al.  High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  T. Kondo,et al.  Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma. , 2015, The Annals of thoracic surgery.

[26]  H. Sekhon,et al.  Aerogenous metastases: a potential game changer in the diagnosis and management of primary lung adenocarcinoma. , 2014, AJR. American journal of roentgenology.

[27]  Prasad S Adusumilli,et al.  Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation , 2014, The American journal of surgical pathology.

[28]  W. Stringer,et al.  Lepidic predominant adenocarcinoma with aerogenous spread of mucin in a young patient -- a case report. , 2014, Experimental and molecular pathology.

[29]  I. Petersen,et al.  CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[30]  M. Ladanyi,et al.  KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma , 2013, Modern Pathology.

[31]  M. Ladanyi,et al.  Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. , 2013, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[32]  Michael Thomas,et al.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. A. McIvor,et al.  Severe bronchorrhea in a patient with bronchioloalveolar carcinoma. , 2012, Chest.

[34]  Zoe Wainer,et al.  Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[36]  M. Ladanyi,et al.  Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. , 2011, The Journal of molecular diagnostics : JMD.

[37]  G. Rossi,et al.  A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  S. Murashima,et al.  Resection of mucinous lung adenocarcinoma presenting with intractable bronchorrhea. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  Chris Sander,et al.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.

[40]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[41]  M. Gaeta,et al.  Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. , 2003, Lung cancer.

[42]  J. Fujita,et al.  Evaluation of the Clonality of Multilobar Bronchioloalveolar Carcinoma of the Lung: Case Report , 2002, American journal of clinical oncology.

[43]  W. Stetler-Stevenson,et al.  Comparison of Extracellular Matrix Antigens in Subtypes of Bronchioloalveolar Carcinoma and Conventional Pulmonary Adenocarcinoma: An Immunohistochemical Study , 1992, The American journal of surgical pathology.